Nonscarring Inflammatory Alopecia Associated With the Epidermal Growth Factor Receptor Inhibitor Gefitinib

Gefitinib, an oral anticancer agent that inhibits the epidermal growth factor receptor (EGFR), was associated with various cutaneous side effects, including nonscarring inflammatory alopecia. The document presented a case of a woman who developed extensive nonscarring inflammatory alopecia after 2 years of gefitinib therapy. This case highlighted the role of EGFR signaling in skin health and the potential for significant dermatological side effects from EGFR inhibitors.